This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

20 Jul 2011

Lonza Signs Manufacturing Deal with Immune Pharmaceuticals for Monoclonal Antibody

Lonza has won a contract to manufacture Immune Pharmaceuticals' antibody-based drug for inflammatory disorders.

Swiss drugmaker Lonza has signed a manufacturing deal with Immune Pharmaceuticals for human immunoglobulin monoclonal antibody, Bertilimumab, which is under investigation for the potential treatment of several inflammatory diseases.


Bertilimumab is the first monoclonal antibody that will specifically neutralise human eotaxin-1, a chemokine associated with inflammatory disease activity.


Under the agreement with Immune Pharmaceuticals, Lonza will produce phase 2 clinical trial material at its mammalian development and manufacturing facility.


Stephan Kutzer, coo at Lonza Custom Manufacturing, said this partnership is a direct reflection of its commitment to emerging pharmaceutical companies as the

Related News